CBDBuzzz.com
  • Home
  • News
  • Culture
  • Science
  • Health
  • Videos
  • Shop
No Result
View All Result
CBDBuzzz.com
  • Home
  • News
  • Culture
  • Science
  • Health
  • Videos
  • Shop
No Result
View All Result
CBDBuzzz.com
No Result
View All Result

Current Clinical Trial Assessing Potential of CBD in Treatment of Autism

July 15, 2020
in Science
Reading Time: 3 mins read
A A
Current Clinical Trial Assessing Potential of CBD in Treatment of Autism
401
SHARES
2.4k
VIEWS
ShareShareShareShareShare

Researchers at University of California San Diego School of Medicine are recruiting eligible children between the ages of seven and fourteen years for a Phase III clinical trial to determine whether cannabidiol (CBD) reduces severe behavior problems in children with autism spectrum disorder (ASD).

CBD is a non-psychoactive compound found in the cannabis plant. It is widely marketed for diverse therapeutic benefits, from reducing chronic pain, acne and anxiety to treating cancer. In most cases, however, supporting empirical evidence is scant or non-existent.

One exception is the use of CBD to treat two forms of severe epilepsy. In 2018, the U.S. Food and Drug Administration approved the use of Epidiolex, prescription solution of highly purified CBD developed by Boston-based Greenwich Biosciences, to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome.

CBD has been found to modulate nerve cell messages in regions of the brain regulating anxiety, executive function and behavior, blocking signals to key neuronal receptors that, when overstimulated, may trigger seizures.

“Studies using animals modeling ASD have shown that CBD has similar effects: Excitatory neurotransmitters are inhibited, leading to a reduction of behavioral and social deficits characteristic of ASD,” said Doris Trauner, MD, Distinguished Professor of Neurosciences and Pediatrics at UC San Diego School of Medicine and an attending pediatric neurologist at Rady Children’s Hospital-San Diego with special expertise in neurodevelopmental disabilities. “CBD may have potential for many neurological disabilities, but there is particular interest in autism because the behavioral problems can be severe and limit the child’s ability to learn and socialize.”

Trauner is principal investigator of the current clinical trial: a randomized, double-blind crossover study that seeks 30 participants, ages 7 to 14, with diagnosed cases of autism and severe symptoms. Children with epilepsy are excluded from the study. All participants will receive behavioral testing, MRI scans and electroencephalograms.

In the first phase of the study, half of the participants will receive CBD and the other half a placebo; both in the form of self-administered, flavored oral drops. In the second phase, after a period to allow participants’ systems to “washout,” the groups will be switched with the half that originally received CBD getting the placebo while the initial placebo group receives CBD. Investigators will be blinded to which participants are receiving which treatment until after testing is completed.

CBD does not produce the effects of feeling “high,” which are caused by tetrahydrocannabinol or THC (the psychoactive ingredient in marijuana). But as one of more than 100 compounds called cannabinoids in cannabis, CBD interacts with the body’s endocannabinoid system, a network of neurotransmitters that regulate diverse physiological and cognitive processes and response to stress.

ASD affects an estimated one in 68 children in the United States, primarily boys. The neurodevelopmental disorder is complex, with multiple known or suspected causative factors, from inherited genetic mutations to environmental conditions to metabolic dysfunction. A major consequence is abnormal development and functioning of connectivity and communications between brain cells and among neural networks, resulting in many of the observed social and cognitive impairments in persons with ASD.

The clinical trial is funded by a gift from the Ray and Tye Noorda Foundation, in partnership with the Wholistic Research and Education Foundation, and based at the Center for Medicinal Cannabis Research  at UC San Diego School of Medicine.

For more information on the CBD-autism clinical trial, contact Lauren Smith at lmsmith@ucsd.edu or 619-627-1133.

Credit: Source link

Share160Tweet100SendShare28Pin36
Previous Post

Israel, el mayor importador mundial de cannabis medicinal

Next Post

High Times Greats: D.A. Pennebaker

Related Posts

Trump says Harris ‘lied’ when questioned on cannabis (Newsletter: August 13, 2020)
Science

Schumer hosts cannabis meeting with other lawmakers (Newsletter: February 2, 2023)

February 2, 2023
Aurora Cannabis Inc. (TSE:ACB) Receives Average Recommendation of “Hold” from Analysts
Science

Aurora Cannabis (ACB) Scheduled to Post Quarterly Earnings on Thursday

February 2, 2023
The White House Is Reviewing CBD And Marijuana Research Guidance From FDA
Science

What New Federal Cosmetics Rules Mean For Products Made With CBD And Other Cannabis Derivatives (Op-Ed)

February 1, 2023
Deming Cannabis Co. helps bring life to west side
Science

Deming Cannabis Co. helps bring life to west side

February 1, 2023
Load More
Next Post
High Times Greats: D.A. Pennebaker

High Times Greats: D.A. Pennebaker

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Updates

28 grams of game: Shiest Bubz is legend

28 grams of game: Shiest Bubz is legend

February 3, 2023
Australia to allow magic mushrooms and MDMA for limited medical use

Australia to allow magic mushrooms and MDMA for limited medical use

February 3, 2023
Surprise, Missouri! State opens adult-use marijuana sales three days early

Surprise, Missouri! State opens adult-use marijuana sales three days early

February 3, 2023
Yale Announces New Cannabis Research Center

Yale Announces New Cannabis Research Center

February 3, 2023
UC Davis Launches Institute for Psychedelics and Neurotherapeutics

UC Davis Launches Institute for Psychedelics and Neurotherapeutics

February 3, 2023
CBDBuzzz.com

This is an online news portal that aims to share latest news about "News, Culture, Science, Health, Shop" and much more stuff like that. Feel free to get in touch with us!

Recent News

28 grams of game: Shiest Bubz is legend

28 grams of game: Shiest Bubz is legend

February 3, 2023
Australia to allow magic mushrooms and MDMA for limited medical use

Australia to allow magic mushrooms and MDMA for limited medical use

February 3, 2023

Subscribe Now

Loading
  • Contact Us
  • Privacy Policy

© 2020 matans3.sg-host.com - All rights reserved!

No Result
View All Result
  • Home
  • News
  • Culture
  • Science
  • Health
  • Videos
  • Shop

© 2020 matans3.sg-host.com - All rights reserved!